Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Average (2016 - 2025)

Iovance Biotherapeutics has reported Equity Average over the past 9 years, most recently at $700.4 million for Q4 2025.

  • Quarterly results put Equity Average at $700.4 million for Q4 2025, down 5.59% from a year ago — trailing twelve months through Dec 2025 was $700.4 million (down 5.59% YoY), and the annual figure for FY2025 was $704.5 million, up 8.8%.
  • Equity Average for Q4 2025 was $700.4 million at Iovance Biotherapeutics, roughly flat from $700.4 million in the prior quarter.
  • Over the last five years, Equity Average for IOVA hit a ceiling of $771.0 million in Q3 2024 and a floor of $511.0 million in Q1 2023.
  • Median Equity Average over the past 3 years was $700.4 million (2025), compared with a mean of $677.7 million.
  • Biggest five-year swings in Equity Average: grew 23.75% in 2024 and later dropped 9.16% in 2025.
  • Iovance Biotherapeutics' Equity Average stood at $629.3 million in 2023, then increased by 17.9% to $741.9 million in 2024, then dropped by 5.59% to $700.4 million in 2025.
  • The last three reported values for Equity Average were $700.4 million (Q4 2025), $700.4 million (Q3 2025), and $733.2 million (Q2 2025) per Business Quant data.